13FPulse
AG

AGL AGILON HEALTH INC

2026Q2 · CUSIP 00857U206 · Sector: Healthcare & Biotech

Piling in

Net holder growth ranks near the top of the market

Funds that own it
174
Institutions that reported holding it to the SEC
Net increase in holders
+80
Last quarter 94 → now 174
How unusual is that
Top 5%
Stronger buying than 97% of US stocks
What the filings say, in one paragraph

174 funds held AGL at the end of 2026Q2, up 80 from the quarter before. That is stronger buying than 97.4% of US stocks — among the most piled-into names this quarter. AGL has had 2 buying rushes in its history. It sits in the Healthcare & Biotech sector.

How many funds owned it, quarter by quarter

Bars = net change in institutional holders, positive (green) or negative (red). Line = total institutional holders.

2025Q3: holders=1 2025Q4: holders=1 2026Q1: holders=94 2026Q2: holders=174 -93 -46.5 +0 +46.5 +93 092183 25Q325Q426Q126Q2 Net change in holders (bars) Total funds holding (line)

What happened after each past buying rush 2 times in its history

Quarter of the rush How unusual then Price, next 3 months Price, next 6 months
2026Q2 Top 5%
2026Q1 Top 5%

These are the raw price moves, not how much it beat the market by. Compare them against the market over the same months — in a strong bull market almost everything is up.

Show all the numbers (large funds, value held, options…) ▾
Of them, large funds
97
Change in large funds
+46
Total value they hold
$1.7B
Funds buying for the first time
93
Funds that sold out entirely
13
Price change that quarter
+0.7%
Funds holding puts (bearish)
6
Funds holding calls (bullish)
7

These are for people who want to dig. Skip them if they do not mean anything to you — the three numbers above are enough.

8,697 institutions have filed for this quarter. 13F permits late filing and a small number arrive in the weeks after the deadline, so the holder counts and changes below may tick up.

Email me the next update

2026 Q3 holdings are due 2026-11-16. We will email you when the refreshed lists are live.